Answers are grounded in this paper and cite their sources.
This retrospective study aimed to identify clinical factors associated with progression-free survival (PFS) after radioiodine therapy (RAI) in Japanese patients with differentiated thyroid cancer (DTC) and pulmonary metastases. We included 74 patients with DTC and pulmonary metastases who underwent RAI at our institution between 2015 and 2023. Baseline clinicopathological, laboratory, and imaging variables at the initial RAI for pulmonary metastases were evaluated. PFS and overall survival (OS) were estimated using the Kaplan–Meier method. Because 27 PFS events were observed, associations with PFS were evaluated using Firth's penalized Cox regression. The primary multivariable model included the maximum pulmonary metastasis diameter, iodine-131 avidity, and extrapulmonary distant metastases. The cohort included 64 patients with papillary thyroid carcinoma, 7 with follicular thyroid carcinoma, and 3 with poorly differentiated thyroid carcinoma. During a median follow-up of 21.1 months, 27 patients experienced disease progression or death, and 10 died. The median PFS and OS were 46.3 and 76.0 months, respectively. In the primary multivariable model, a larger maximum pulmonary metastasis diameter (hazard ratio [HR] per 10-mm increase, 1.85; 95% confidence interval [CI], 1.20–2.73; p = 0.006) and absence of iodine-131 uptake (HR, 6.15; 95% CI, 1.73–37.55; p = 0.003) were associated with poorer PFS. The association between extrapulmonary distant metastases and PFS was not statistically significant in this model. Larger pulmonary metastases and absence of iodine-131 uptake were associated with poorer PFS after RAI. These findings require cautious interpretation and validation in larger independent cohorts.
No takes yet. Share an insight, caveat, or question.
Hasegawa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: